Coordination Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06182579
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05838729
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Phase I Study of CPI-300 in Patients With Advanced Tumors
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04808453
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study of CPI-200 in Patients With Advanced Tumors
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03953742
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START Midwest), Grand Rapids, Michigan, United States
Study of CPI-100 in Patients With Advanced Tumors
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03781362
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Prev
- 1
- 2
- Next